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Background: Despite the high prevalence of anxiety in COPD patients and its impact on 
quality of life, evidence to support the effectiveness of various anxiety treatment options is 
insufficient, leading to the need for further research in this field.
Aim: The aim of this study was to assess the efficacy and safety of paroxetine for the manage-
ment of anxiety in COPD and the impact of treatment on patients’ quality of life and rate of 
hospitalization.
Patients and methods: In a double-blind, randomized, controlled trial, COPD patients were 
allocated into groups that either received paroxetine 20 mg or placebo pills daily, for four months. 
Differences in outcomes were assessed based on an intention-to-treat analysis using linear mixed 
effects models. A chi-square test was used to compare the number of COPD-related admissions.
Results: Thirty-eight participants were recruited. Twenty-two of these completed the trial. A 
clinically and statistically significant reduction was noted in anxiety symptoms after four months 
of treatment compared to the placebo. Clinically important improvement was noted in depres-
sion symptoms, with no statistically significant differences in walking distance or quality-of-life 
measure outcomes. The intervention group had less COPD-related admissions compared to the 
placebo group but experienced medication-related side effects.
Conclusion: Treatment with paroxetine significantly improved anxiety levels, but this differ-
ence did not translate into improved quality of life at four months follow-up.
Keywords: anxiety, COPD, pharmacotherapy, paroxetine, BAI, emphysema
Introduction
COPD is one of the most common chronic medical conditions worldwide with a 
prevalence range of 7.8–19.7%.1 Importantly, this estimate is predicted to double 
by 2050.2 Anxiety and depression are common comorbidities of people with COPD, 
which are frequently undertreated or not treated at all.3 Anxiety is two- to threefold 
more common in COPD patients (10–15.8%4) as compared to the general population, 
with a lifetime prevalence of 5%.5
There are various physiological and pathological mechanisms that could be respon-
sible for the increased levels of anxiety and panic in people with COPD.6,7 For example, 
COPD individuals frequently experience dyspnea and palpitations, which could be 
misinterpreted as serious or catastrophic events by the brain or body, leading to the 
creation of a positive feedback loop resulting in anxiety and panic.8,9
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Coexisting anxiety among people with COPD is commonly 
associated with a deterioration in quality of life,10 self-man-
agement,11 exercise performance,12 and an increase in medical 
symptom reporting,13 illness exacerbations,12 hospitalizations,14 
length of hospital stay,15 mortality,16 and health care costs.13 The 
impact of anxiety and depression on health-related outcomes 
in these individuals is independent of other confounding fac-
tors such as general health status, comorbidities, and disease 
severity.4 It has even been reported that the functional status of 
COPD patients is more dependent on their emotional status as 
compared to the actual severity of COPD itself.17,18
In clinical practice, pharmacological therapies are usu-
ally used as first-line therapy to treat anxiety in people with 
COPD. However, there is limited evidence to support this 
practice within the COPD population.19,20 There is currently 
a lack of randomized controlled trials to assess the effects 
of pharmacological interventions in people with COPD. The 
studies which are available have methodological limitations 
in terms of small sample size, large dropout rates, or a short 
follow-up period.19,21
Despite the lack of evidence, selective serotonin reuptake 
inhibitors (SSRIs) have been widely used in clinical practice 
for treating depression and anxiety in people with COPD. 
In our published Cochrane systematic review, we identified 
a potentially useful clinical improvement favoring the use 
of SSRIs over that of placebo for controlling anxiety in an 
underpowered study, while little or no difference was found 
for the other classes of medications.21 Unlike other SSRIs, 
paroxetine is indicated for the treatment of both depression 
and anxiety,22,23 which is of relevance in COPD sufferers. 
Another study of paroxetine in people with COPD and 
comorbid depression showed significant improvements in 
depressive symptoms, exercise capacity, and quality of life 
at three months follow-up.24 However, this study was under-
powered, and the authors concluded that a larger, double-blind 
trial with a relatively longer treatment period was indicated. 
As such, a case can be made that a study of robust design 
and appropriate power is warranted.
Our study tested the hypothesis that people with COPD 
and clinically significant anxiety, recruited from public 
hospitals, who are prescribed 20 mg of paroxetine (Pharma-
ceutical Packaging Professionals Pty Ltd., Port Melbourne, 
VIC, Australia) daily for 16 weeks will:
(Hypothesis 1: principle hypothesis) have a significant 
reduction in their anxiety symptoms measured by Beck 
Anxiety Inventory (BAI) as compared with the placebo at 
four months follow-up, and
(Hypothesis 2) will experience improved quality of life 
measured by Chronic Respiratory Questionnaire (CRQ), 
and exercise capacity measured by six-minute walk distance 
(6MWD), and
(Hypothesis 3) have reduced hospital visits.
Methods
ethical approval
The trial was approved by the Human Research and Ethics 
Committee of The Queen Elizabeth Hospital, Adelaide, SA 
(HREC Ref # 2012012). The trial was registered with the 
Australian and New Zealand Clinical Trials Registry (Trial 
ID: ACTRN12613000458730) in April 2013, and participant 
recruitment began in June 2013.
Design
The trial was double blind, placebo controlled, with random-
ization to either:
1. paroxetine 20 mg daily (four-month course);
2. placebo tablets of identical appearance (four-month 
course).
Hospital sampling frame and recruitment
The sampling frame included four Adelaide Hospitals, The 
Queen Elizabeth Hospital (TQEH), Repatriation General 
Hospital (RGH), Flinders Medical Centre (FMC), and the 
Royal Adelaide Hospital (RAH), which collectively have 
more than 40,000 admissions per year. Of these, at least 4,000 
admissions are for patients diagnosed with COPD.
inclusion criteria
Patients who met the following criteria were included in the 
trial: adults over 40 years of age, diagnosed with any class of 
COPD of any severity (by a medical consultant or by Global 
initiative for chronic Obstructive Lung Disease [GOLD] 
criteria: post-bronchodilator forced expiratory volume in one 
second [FEV1]/forced vital capacity <0.7025), and recognized 
as having clinically significant anxiety, with a score of >15 
as assessed using BAI.26
The BAI has been validated for use with older medical 
patients,27 and the scale possesses strong psychometric prop-
erties related to internal consistency, validity, and test–retest 
reliability.28 The BAI can be used to assess and establish a 
baseline anxiety level, as a diagnostic aid, and also as a post-
treatment outcome measure.
The BAI is a 21-question multiple-choice self-report 
inventory used for measuring the severity of anxiety. Total 
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scores ranging from 0 to 7 are indicative of minimal anxiety, 
8–15 of mild anxiety, 16–25 of moderate anxiety, and 26–63 
of severe anxiety. However, it is worth noting that the BAI 
includes numerous somatic symptoms that may represent 
COPD rather than anxiety, so COPD patients with anxiety 
scores at the very mild end of the scale should be treated 
cautiously. A score of >15 was categorized as moderate or 
severe anxiety28 and has been used in previous studies as the 
“cutoff ” for anxiety in people with COPD;17 hence, a BAI 
score of >15 was chosen to define clinical anxiety.
exclusion criteria
Patients with any of the following criteria were excluded: 
current or recent (within a week) exacerbation of COPD; 
severe dementia or significant cognitive impairment, terminal 
cancer, or other concurrent significant psychological disease 
(e.g., schizophrenia or suicidal ideation); history of current 
or recent (within last two weeks) use of monoamine oxidase 
inhibitors; Prolonged QT interval (>440ms in males and 
>460ms in females) on ECG; current pregnancy or lactation; 
severe liver, kidney, cardiovascular, or locomotor disease; 
uncontrolled epilepsy or previous history of SSRI intolerance.
randomization, allocation concealment, 
and blinding
All the participants were provided with written informed 
consent and signed the consent prior to being enrolled in 
the study. Randomization was accomplished by a random 
number generator computer software program, by an external 
researcher unrelated to the trial. Allocation concealment and 
blinding were maintained for patients, investigators, research/
data collection staff, and outcome assessors by using an 
external pharmacy dispensing company to package the study 
medication as per the randomization schedule into identical 
containers, which were consecutively numbered. This medi-
cation was then dispensed by the hospital pharmacy as each 
new participant was recruited. However, if a subject experi-
enced a serious adverse event, the treatment was ceased, and 
the code was broken by a research pharmacist unrelated to 
the trial, resulting in all trial staff remaining blinded.
intervention delivery and monitoring
Research staff blinded to the treatment allocation commenced 
patients on 20 mg of paroxetine or an identical placebo pill 
during their first visit for baseline measurements. Patients 
were provided with contact details of research personnel for 
notification of adverse events. The medication was provided 
for 16 weeks with a weekly phone call for the first four weeks 
to identify and address any side effects or adverse events. 
This procedure is summarized in Figure 1.
Data collection
Baseline questionnaires
Patient demographic characteristics including age, gender, 
ethnicity, and marital and smoking status were collected. 
Details regarding the diagnosis and severity of COPD and 
other medical comorbidities were also documented, and 
a detailed note was made of all concomitant medications. 
Primary outcome of anxiety was measured using BAI. 
Secondary outcomes included depression measured using 
Beck Depression Inventory (BDI),29 quality of life assessed 
via CRQ,30 and dyspnea assessed using modified Medical 
Research Council dyspnea scale.31,32 Smoking status, 6MWD, 
and spirometry were also documented.
Follow-up questionnaires
Weekly phone calls were made for the first four weeks to 
assess compliance and any intervening management, and 
for adverse events monitoring. The prespecified outcomes of 
anxiety, depression, quality of life, dyspnea score, 6MWD, 
spirometry, and hospital utilization were reassessed at four 
months during a face-to-face visit.
Withdrawal criteria
The withdrawal criteria included any clinically significant 
adverse event that was considered related to the study and 
patients’ unwillingness to continue further with the trial.
statistical analysis
Very few previous studies were available to guide the origi-
nal power calculation. One study had shown an effect size 
of 1.0;33 however, we chose a more conservative effect size 
estimate of 0.5, based on a linear mixed effects model with 
two time points, a power of 80%, a type 1 error of 0.05, and 
an expected correlation between baseline and four-month 
results of 0.4. This required a sample size of 50 patients in 
each study arm. However, after three years of an intense 
recruitment campaign, only 38 participants could be recruited 
and were randomized to either placebo or intervention group. 
An intention-to-treat analysis was conducted by the trial 
statistician to determine if significance was reached and the 
study could be discontinued. Linear mixed effects models 
were used to assess change score by group. The fixed factors 
consisted of group, time, and a group–time interaction term, 
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the latter being the basis for a formal test of the intervention. 
A chi-square test was used to compare the number of COPD-
related admissions by group.
Results
Participants
A total of 208 patients were screened for eligibility (Figure 1). 
More than half of these did not meet the prespecified inclu-
sion criteria. Ninety patients were approached for enrollment, 
and more than half of these could not be included primarily 
due to a lack of interest for participation or because their 
BAI score was <15. Thirty-eight participants were enrolled 
during three years of recruitment.
Demographics for this population were similar between 
groups with no statistically or clinically significant differ-
ences observed (Table 1). Two participants in each group had 
past history of depression. The mean FEV1 in the intervention 
group was 44.7% versus mean FEV1 in placebo group of 
35.8%, however, from a clinical perspective, both averages 
were within the range for severe COPD or GOLD stage III 
classification.
Eighteen participants were randomized to the intervention 
group, with eight of these lost to follow-up and therefore 
not available for the four-month questionnaire. Out of these 
eight patients, one suffered severe nausea and dizziness as a 
side effect of the intervention, two passed away for reasons 
unrelated to the trial, and five refused follow-ups for various 
Figure 1 Flowchart of the study.
Abbreviation: Bai, Beck anxiety inventory.
Medical records/notes screened for eligibility
n=208
Patients approached for possible participation
n=90
Patients not meeting
inclusion
criteria n=118
Patients recruited and randomized n=38
Intervention n=18 Placebo n=20
Withdrawn n=8
Did not want to
participate further n=6
Adverse event n=1
Death n=1
Withdrawn n=8
Did not want to
participate further
n=5
Adverse event n=1
Death n=2
Excluded following discussion n=52
Did not want to participate n=23
Did not reach BAI cutoff n=21
Other inclusion criteria not
met n=8
Completed four-month
data collection n=10
(intention to treat)
Completed four-month
data collection n=12
(intention to treat)
Completed four-month
intervention n=10
Completed four-month
placebo n=12
Table 1 Baseline demographic characteristics
Demographics Intervention  
(n=18)
Placebo  
(n=20)
age (years) 70.6 (9.0) 67.6 (7.7)
Males:females (n) 9:9 11:9
cOPD severity (FeV1%) 44.7 (18.0) 35.8 (16.1)
BMi (kg/m2) 25.7 (6.6) 28.5 (5.5)
Pulmonary rehabilitation: yes (n, %) 2 (11.1%) 3 (15.0%)
ethnicity (n, %)
caucasian 18 (100%) 20 (100%)
Other 0 0
educational attainment (n, %)
High school or less 17 (94.4%) 18 (90%)
some college 0 0
college degree or higher 1 (5.6%) 2 (10.0%)
Household income (n, %)
low income (≤$20kp.a.) 10 (55.6%) 12 (60.0%)
Medium income ($20–$50kp.a.) 4 (22.2%) 5 (25.0%)
Unknown income 4 (22.2%) 3 (15.0%)
smoking status (n, %)
current smoker 6 (33.3%) 5 (33.3%)
ex-smoker 18 (66.7%) 15 (66.7%)
Note: Data are presented as mean (standard deviation) unless otherwise specified.
Abbreviations: FeV1, forced expiratory volume in one second; BMi, body mass 
index; kp.a., thousand per annum.
 
Jo
ur
na
l o
f M
ul
tid
isc
ip
lin
ar
y 
He
al
th
ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
30
 o
n 
25
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Multidisciplinary Healthcare 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
291
Paroxetine for the management of anxiety in cOPD
reasons (two changed their mind and did not wish to continue, 
one developed other health priorities, one reported signifi-
cant worsening of anxiety, and one experienced significant 
deterioration of health).
Twenty participants were randomized to the control 
group. Eight of these were lost to follow-up and were not 
available for the four-month questionnaire. Of these eight 
patients, one suffered severe headaches as a side effect of 
placebo, one passed away for reasons unrelated to the trial, 
and six refused follow-ups for various reasons (two changed 
their minds and did not wish to continue, two had general 
deterioration of health, one developed other health priori-
ties, and one reported significant worsening of anxiety and 
did not wish to continue). No significant difference was 
noted in terms of COPD severity between the patients who 
completed the trial versus those who lost the follow-up in 
either of the groups.
Subsequently, data from 10 participants in the interven-
tion and 12 participants in the placebo group were available 
for the intention-to-treat analysis. Of these subjects, seven 
in the intervention and six in the placebo group completed 
the entire course of 120 capsules. The number of capsules 
returned by the other participants was minimal and ranged 
between 4 and 17. However, it is expected that uninten-
tional missed doses would not cause any significant clinical 
impact, particularly in the setting of proper randomization 
and blinding.
Treatment effect
For the primary outcome of anxiety (BAI), participants 
in the intervention group had a greater improvement after 
four months compared to the placebo group (Table 2). The 
difference was both statistically and clinically significant 
(p=0.007). Mean change (reduction) of 11.9 units of BAI 
was noted in the intervention group versus 3.16 units in the 
placebo group.
Clinically important improvement in the treatment group 
(with a mean change of 4.5 units of BDI) was noted for 
depression symptoms compared to the placebo group. Nei-
ther clinical nor statistical difference was noted for dyspnea, 
walking distance, or quality-of-life outcomes.
There were fewer COPD-related hospital admissions in 
the intervention group compared to the placebo group during 
the four-month treatment phase (1/10 and 6/12, respectively; 
p=0.050). However, this was based on a small number of 
admissions and shorter follow-up period. More side effects 
were reported in the intervention arm compared to the pla-
cebo arm (Table 3).
Discussion
COPD is one of the most common medical conditions 
worldwide, and comorbid anxiety is frequently seen in 
people suffering from COPD. Anxiety when associated with 
COPD also has a significant impact on patients’ exercise 
capacity and quality of life. There is evidence that the rate of 
Table 2 Outcome scores at baseline and follow-up with differences between groups
Outcome measured Intervention (n=10) Placebo (n=12) p-value*
Baseline Follow-up Change Baseline Follow-up Change
anxiety (Bai) 26.80 (7.4) 14.90 (8.8)
−11.9 25.25 (8.2) 22.09 (11.8) −3.16 0.007
Depression (BDi) 16.20 (10.7) 11.70 (10.5)
−4.5 14.58 (8.2) 15.92 (10.6) 1.34 0.144
Dyspnea (mMrc dyspnea scale) 2.00 (1.2) 2.00 (1.2) 0.0 2.17 (1.1) 2.42 (0.9) 0.25 0.684
6MWD (m) 311.90 (132.9) 329.13 (115.7) 17.23 294.45 (115.7) 354.56 (62.0) 60.11 0.301
crQ
Dyspnea 3.62 (0.9) 3.80 (1.4) 0.18 3.50 (1.2) 3.48 (1.4)
−0.02 0.775
Fatigue 3.42 (1.0) 3.83 (1.3) 0.41 3.42 (1.4) 2.84 (0.7)
−0.58 0.089
emotional 3.68 (1.2) 4.83 (1.1)
−1.55 3.76 (1.4) 4.19 (1.3) 0.43 0.196
Mastery 3.25 (1.3) 4.25 (1.3) 1.0 3.52 (1.7) 4.00 (0.8) 0.48 0.270
Notes: Data are presented as mean (standard deviation). *Based on the statistical significance of the group–time interaction term in the linear mixed effects model.
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; m, meters; mMRC, modified Medical Research Council; 6MWD, six-minute walk distance; 
crQ, chronic respiratory Questionnaire.
Table 3 cOPD-related hospital admissions and adverse events 
during treatment period
Side effects Intervention Placebo
Headache 1 1
Heart burn 1 0
insomnia 1 0
itch 0 1
nausea 1 0
stomach upset 1 0
shakes 1 0
Tiredness 0 1
Vertigo 0 1
Total adverse events 6 4
 
Jo
ur
na
l o
f M
ul
tid
isc
ip
lin
ar
y 
He
al
th
ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
30
 o
n 
25
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Multidisciplinary Healthcare 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
292
Usmani et al
 hospitalization is also increased among these patients, possi-
bly due to noninfective presentations or primary presentations 
because of panic and then being found to have low oxygen 
saturation due to underlying COPD and admitted to hospital.
Despite the impact of psychological comorbidities, the 
major focus of clinical practice and research still focuses on 
improvement in lung function, rather than patients’ emotional 
and psychological well-being.
As discussed above, previous trials for the pharmacologi-
cal treatment of anxiety in people with COPD were of small 
sample size; hence, we decided to conduct a larger clinical 
trial. However, the difficulty we faced in terms of recruitment 
and retention of the participants has further confirmed the 
complex nature and management issue surrounding these 
patients and may explain the small sample size of previous 
trials.
This study has shown that a four-month course of parox-
etine reduces anxiety levels in people with COPD compared 
to placebo, albeit based on a small sample size. It is impor-
tant to note that anxiety and depression often coexist, and 
although not statistically significant, our study demonstrated 
a clinically significant improvement in depression scores 
for the treatment arm, measured by BDI. However, at four 
months, these improvements in anxiety and depression scores 
did not translate into improvement in exercise capacity or 
quality of life; a longer duration of treatment may be required 
to prompt this. Another possible explanation for this lack of 
effect on exercise capacity and quality of life could be that 
though the medication has calmed the patients, it has not 
modified their thought process and behavior, an effect which 
could be achieved by adding a psychological intervention. 
Both the study arms experienced similar rates of withdrawal; 
however, side effects of nausea, stomach upset, and shakes 
were more common in the treatment group; these are com-
mon and expected side effects of SSRIs. The incidence of 
hospital admission was less in the treatment group compared 
to placebo, though the follow-up period was short. Hence, 
we remain cautious about drawing firm conclusions on this. 
One explanation for the reduced admission rate could be 
associated with a reduction in anxiety levels resulting in a 
lesser number of self-presentations due to stress and panic.
We observed a significant reduction in anxiety levels and 
some reduction in depression and hospitalization rates over 
a short follow-up period. It is possible that the large change 
in BAI may be related to the difference in the underlying 
nature of the anxiety disorder; for example, the intervention 
arm may have had a larger proportion of participants with 
panic disorder. However, we did not perform any stratification 
during the randomization of participants based on their levels 
of anxiety or the nature of their underlying anxiety disorder. 
We believe one of the most important messages of this study 
comes from issues with patient recruitment and retention, 
being that this particular group of people with COPD are 
difficult to engage due to their underlying panic and stress. 
This is also likely to be the underlying reason for these indi-
viduals demonstrating a low threshold for discontinuing their 
medication and becoming lost from close clinical follow-up. 
We recommend that further research into the problem of 
anxiety in people with COPD be focused on psychological 
interventions, for example, cognitive behavioral therapy, as 
this type of intervention could modify patients’ behavior and 
thought process, without the introduction of side effects and 
hence may be a better long-term management option for this 
population.
Acknowledgments
The authors wish to acknowledge Harshani Jayasinghe and 
Malcolm Brinn for their assistance with patient recruitment 
and data collection and Zoe Kopsaftis for assistance with 
manuscript editing. They also wish to thank June Challen 
from the Clinical Trials Unit at TQEH pharmacy for assis-
tance with blinding and randomization along with Pamela 
Kidd and Donna Keatley from the Pulmonary Function 
Laboratory at TQEH Respiratory Medicine for assistance 
with performing various tests. They wish to thank Dr Paul 
Cafarella (RGH), Dr Jeff Bowden (FMC), Dr Ral Antic 
(RAH), Prof Mark Holmes (RAH), Mrs Karen Royals 
(TQEH), and Mrs Mary Young (RAH) for their assistance 
with recruitment at various sites. This study was funded by the 
Department of Respiratory Medicine, The Queen Elizabeth 
Hospital, Adelaide, SA, Australia.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global 
strategy for the diagnosis, management and prevention of COPD. 2016. 
Available from: http://goldcopd.org/. Accessed 2018.
2. Access Economics Pty Limited. Economic impact of COPD and cost 
effective solutions. The Australian Lung Foundation; 2008.
3. Cully JA, Graham DP, Stanley MA, et al. Quality of life in patients 
with chronic obstructive pulmonary disease and comorbid anxiety or 
depression. Psychosomatics. 2006;47(4):312–319.
4. Brenes GA. Anxiety and chronic obstructive pulmonary disease: preva-
lence, impact and treatment. Psychosom Med. 2003;65(6):963–970.
5. Wittchen HU, Hoyer J. Generalised anxiety disorder: nature and course. 
J Clin Psychiatry. 2001;62 Suppl 11:15–19.
6. Ley R. Agoraphobia, the panic attack and the hyperventilation syn-
drome. Behav Res Ther. 1985;23(1):79–81.
 
Jo
ur
na
l o
f M
ul
tid
isc
ip
lin
ar
y 
He
al
th
ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
30
 o
n 
25
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Multidisciplinary Healthcare 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Journal of Multidisciplinary Healthcare
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal
The Journal of Multidisciplinary Healthcare is an international, peer-
reviewed open-access journal that aims to represent and publish research 
in healthcare areas delivered by practitioners of different disciplines. This 
includes studies and reviews conducted by multidisciplinary teams as well 
as research which evaluates the results or conduct of such teams or health 
care  processes in general. The journal covers a very wide range of areas and 
welcomes submissions from practitioners at all levels, from all over the world. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Dovepress
293
Paroxetine for the management of anxiety in cOPD
7. Perna G, Caldirola D, Bellodi L. Panic disorder: from respiration to the 
homeostatic brain. Acta Neuropsychiatrica. 2004;16(2):57–67.
8. Clark D. A cognitive approach to panic. Behav Res Ther. 1986;24(4): 
461–470.
9. Livermore N, Sharpe L, McKenzie D. Panic attacks and panic disorder 
in chronic obstructive pulmonary disease: a cognitive behavioral per-
spective. Respir Med. 2010;104(9):1246–1253.
10. Giardino ND, Curtis JL, Andrei AC, et al; NETT research group. Anxi-
ety is associated with diminished exercise performance and quality of 
life in severe emphysema: a cross-sectional study. Respir Res. 2010; 
11:29.
11. Dowson CA, Town GI, Frampton C, Mulder RT. Psychopathology and 
illness beliefs influence COPD self-management. Psychosom Res. 
2004;56(3):333–340.
12. Eisner MD, Blanc PD, Yelin EH, et al. Influence of anxiety on health 
outcomes in COPD. Thorax. 2010;65(3):229–234.
13. Katon W, Lin EH, Kroenke K. The association of depression and anxiety 
with medical symptom burden in patients with chronic medical illness. 
Gen Hosp Psychiatry. 2007;29(2):147–155.
14. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospi-
talisation in COPD: role of health status, anxiety and depression. Eur 
Res J. 2005;26(3):414–419.
15. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression 
and anxiety on chronic obstructive pulmonary disease exacerba-
tions and hospitalizations. Am J Respir Crit Care Med. 2008;178(9): 
913–920.
16. Celli BR, Cote CG, Lareay SC, Meek PM. Predictors of survival in 
COPD: more than just the FEV1. Respir Med. 2008;102 Suppl 1: 
S27–S35.
17. Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in 
COPD patients: the impact of anxiety and depression. Psychosomatics. 
2000;41(6):465–471.
18. Atlantis EF, Fahey P, Cochrane B, Smith S. Bidirectional associations 
between clinically relevant depression or anxiety and COPD: a system-
atic review and meta-analysis. Chest. 2013;144(3):766–777.
19. Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety 
and depression in patients with COPD: a literature review. Respirology. 
2012;17(4):627–638.
20. Usmani ZA, Carson KV, Heslop K, Esterman AJ, De Soyza A, Smith 
BJ. Psychological therapies for the treatment of anxiety disorders in 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 
2017;3:CD010673.
21. Usmani ZA, Carson KV, Cheng JN, Esterman AJ, Smith BJ. Phar-
macological interventions for the treatment of anxiety disorders in 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 
2011;11:CD008483.
22. Baldwin DS, Anderson IM, Nutt DJ, et al; British Association for 
Psychopharmacology. Evidence-based guidelines for the pharmaco-
logical treatment of anxiety disorders: recommendations from the 
British Association for Psychopharmacology. J Psychopharmacol. 
2005;19(6):567–596.
23. MIMS USA. Paroxetine. UBM Medica; 2011.
24. Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating 
depression on quality-of-life and exercise tolerance in severe COPD. 
COPD. 2005;2(2):233–241.
25. Global Initiative for Chronic Obstructive Lung Disease. Global strategy 
for the diagnosis, management, and prevention of chronic obstruc-
tive pulmonary disease: executive summary. 2006. Available from: 
goldcopd.org/wp-content/uploads/2018/.../WMS-GOLD-2018-Feb-
Final-to-print-v2.pdf.
26. Steer RA, Ranieri WF, Beck AT, Clark DA. Further evidence for the 
validity of the Beck Anxiety Inventory with psychiatric outpatients. 
J Anxiety Disord. 1993;7(3):195–205.
27. Wetherell JL, Arean PA. Psychometric evaluation of the Beck 
Anxiety Inventory with older medical patients. Psychol Assess. 
1997;9(2):136–144.
28. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring 
clinical anxiety: psychometric properties. J Consult Clin Psychol. 
1988;56(6):893–897.
29. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for 
measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
30. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. 
A measure of quality of life for clinical trials in chronic lung disease. 
Thorax. 1987;42(10):773–780.
31. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. 
Analysis of clinical methods used to evaluate dyspnea in patients with 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
1998;158(4):1185–1190.
32. Mahler DA, Wells CK. Evaluation of clinical methods for rating dys-
pnea. Chest. 1988;93(3):580–586.
33. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH. A random-
ized controlled trial of cognitive behavioral therapy for anxiety and 
depression in COPD. Respir Med. 2010;104(7):986–994.
 
Jo
ur
na
l o
f M
ul
tid
isc
ip
lin
ar
y 
He
al
th
ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
30
 o
n 
25
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
